Transcript:
Did you know that eighty percent of life sciences data is unstructured?
This data is messy, difficult to search, often resides in silos.
Having unstructured data means that you could be missing valuable insights that can inform prioritizing new molecules for designing, executing, or submitting clinical trials.
The proliferation of powerful AI models such as GPTs can help solve this challenge, but most generalized models aren’t amenable to implementation in the life sciences.
In fact, nearly seventy three percent of life science companies still struggle to adopt appropriate AI technologies.
Introducing Certara AI, the life sciences specialized GPT platform.
Traditional GPTs are trained on broad datasets, making them useful at answering general questions, but not so great for life science questions.
By contrast, Certara AI features purpose built GPT models trained specifically on biomedical data.
This intelligent platform understands nuanced life science concepts, enabling drug developers to gain highly specific, and validated insights that meet their requirements.
With the power of Certara AI, life science companies reduce time collecting data, improve research accuracy and accelerate workflows to enable smarter, more efficient drug development. Interested in learning more about Certara AI, visit us online.